380 related articles for article (PubMed ID: 24875858)
1. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.
French CA; Rahman S; Walsh EM; Kühnle S; Grayson AR; Lemieux ME; Grunfeld N; Rubin BP; Antonescu CR; Zhang S; Venkatramani R; Dal Cin P; Howley PM
Cancer Discov; 2014 Aug; 4(8):928-41. PubMed ID: 24875858
[TBL] [Abstract][Full Text] [Related]
2. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.
Grayson AR; Walsh EM; Cameron MJ; Godec J; Ashworth T; Ambrose JM; Aserlind AB; Wang H; Evan G; Kluk MJ; Bradner JE; Aster JC; French CA
Oncogene; 2014 Mar; 33(13):1736-1742. PubMed ID: 23604113
[TBL] [Abstract][Full Text] [Related]
3. NSD3-NUT-expressing midline carcinoma of the lung: first characterization of primary cancer tissue.
Suzuki S; Kurabe N; Ohnishi I; Yasuda K; Aoshima Y; Naito M; Tanioka F; Sugimura H
Pathol Res Pract; 2015 May; 211(5):404-8. PubMed ID: 25466466
[TBL] [Abstract][Full Text] [Related]
4. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.
French CA; Ramirez CL; Kolmakova J; Hickman TT; Cameron MJ; Thyne ME; Kutok JL; Toretsky JA; Tadavarthy AK; Kees UR; Fletcher JA; Aster JC
Oncogene; 2008 Apr; 27(15):2237-42. PubMed ID: 17934517
[TBL] [Abstract][Full Text] [Related]
5. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.
Alekseyenko AA; Walsh EM; Zee BM; Pakozdi T; Hsi P; Lemieux ME; Dal Cin P; Ince TA; Kharchenko PV; Kuroda MI; French CA
Proc Natl Acad Sci U S A; 2017 May; 114(21):E4184-E4192. PubMed ID: 28484033
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of NUT midline carcinoma.
French CA
Annu Rev Pathol; 2012; 7():247-65. PubMed ID: 22017582
[TBL] [Abstract][Full Text] [Related]
7. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma.
Thompson-Wicking K; Francis RW; Stirnweiss A; Ferrari E; Welch MD; Baker E; Murch AR; Gout AM; Carter KW; Charles AK; Phillips MB; Kees UR; Beesley AH
Oncogene; 2013 Sep; 32(39):4664-74. PubMed ID: 23128391
[TBL] [Abstract][Full Text] [Related]
8. The importance of diagnosing NUT midline carcinoma.
French CA
Head Neck Pathol; 2013 Mar; 7(1):11-6. PubMed ID: 23463074
[TBL] [Abstract][Full Text] [Related]
9. Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.
Wang R; Liu W; Helfer CM; Bradner JE; Hornick JL; Janicki SM; French CA; You J
Cancer Res; 2014 Jun; 74(12):3332-43. PubMed ID: 24736545
[TBL] [Abstract][Full Text] [Related]
10. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA
Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of NUT midline carcinoma by epigenomic reprogramming.
Schwartz BE; Hofer MD; Lemieux ME; Bauer DE; Cameron MJ; West NH; Agoston ES; Reynoird N; Khochbin S; Ince TA; Christie A; Janeway KA; Vargas SO; Perez-Atayde AR; Aster JC; Sallan SE; Kung AL; Bradner JE; French CA
Cancer Res; 2011 Apr; 71(7):2686-96. PubMed ID: 21447744
[TBL] [Abstract][Full Text] [Related]
12. NUT midline carcinoma.
French CA
Cancer Genet Cytogenet; 2010 Nov; 203(1):16-20. PubMed ID: 20951314
[TBL] [Abstract][Full Text] [Related]
13. [Utility of NUT gene expression and rearrangement in diagnosis of NUT midline carcinoma in upper respiratory tract].
Fang W; French CA; Cameron MJ; Han YD; Liu HG
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):519-24. PubMed ID: 23157742
[TBL] [Abstract][Full Text] [Related]
14. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
15. Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma.
Yan J; Diaz J; Jiao J; Wang R; You J
J Biol Chem; 2011 Aug; 286(31):27663-75. PubMed ID: 21652721
[TBL] [Abstract][Full Text] [Related]
16. NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment.
French CA
Pathol Int; 2018 Nov; 68(11):583-595. PubMed ID: 30362654
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.
Zhang X; Zegar T; Lucas A; Morrison-Smith C; Knox T; French CA; Knapp S; Müller S; Siveke JT
Oncogene; 2020 Jun; 39(24):4770-4779. PubMed ID: 32366905
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation.
Wang R; You J
J Biol Chem; 2015 Jan; 290(5):2744-58. PubMed ID: 25512383
[TBL] [Abstract][Full Text] [Related]
19. New developments in the molecular pathogenesis of head and neck tumors: a review of tumor-specific fusion oncogenes in mucoepidermoid carcinoma, adenoid cystic carcinoma, and NUT midline carcinoma.
Bhaijee F; Pepper DJ; Pitman KT; Bell D
Ann Diagn Pathol; 2011 Feb; 15(1):69-77. PubMed ID: 21238915
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains.
Alekseyenko AA; Walsh EM; Wang X; Grayson AR; Hsi PT; Kharchenko PV; Kuroda MI; French CA
Genes Dev; 2015 Jul; 29(14):1507-23. PubMed ID: 26220994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
